PT  - JOURNAL ARTICLE
AU  - Scott W. Olesen
AU  - Sanjat Kanjilal
AU  - Stephen M. Kissler
AU  - Daphne S. Sun
AU  - Yonatan H. Grad
TI  - Racial/ethnic disparities in antibiotic use and healthcare utilization, United States, 2016/2018: a cross-sectional study
AID  - 10.1101/2021.12.09.21266965
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.09.21266965
4099  - http://medrxiv.org/content/early/2021/12/11/2021.12.09.21266965.short
4100  - http://medrxiv.org/content/early/2021/12/11/2021.12.09.21266965.full
AB  - Antibiotic prescribing rates vary by patient race/ethnicity, with whites more likely to receive antibiotics and broader-spectrum antibiotics. However, the drivers of this disparity, and to what extent it represents antibiotic overuse or underprescribing of appropriate antibiotic treatment, remains unclear. Here, we investigate how antibiotic prescribing appropriateness varies by race/ethnicity and to what extent disparities in antibiotic use can be explained by differing rates of healthcare utilization. In data from two nationally representative healthcare utilization surveys, we found that racial/ethnic disparities in numbers of healthcare visits, not prescribers’ behavior, better explained disparities in antibiotic prescribing rates. We also found that the proportion of antibiotic prescriptions that were appropriate, potentially appropriate, or inappropriate did not vary significantly by race/ethnicity. These results suggest that whites’ higher antibiotic use is due primarily to increased healthcare utilization and that whites’ higher antibiotic use represents a mix of greater appropriate and inappropriate use. Thus, antibiotic stewardship goals should be informed by research into differing rates of antibiotic-treatable disease and healthcare seeking and access across different populations, to ensure that efforts to reduce inappropriate antibiotic overuse do not also reduce appropriate use in underserved populations.Competing Interest StatementSWO is an employee of Biobot Analytics, Inc. YHG has consulted for GSK, holds grants from Pfizer and Merck, and serves on the scientific advisory board for Day Zero Diagnostics.Funding StatementYHG: Wellcome Trust Award 219812/Z/19/Z and internal Harvard T. H. Chan School award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Source data are openly available from the National Center for Health Statistics (https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Datasets, https://www.cdc.gov/nchs).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource data are openly available from the National Center for Health Statistics (https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Datasets, https://www.cdc.gov/nchs). https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Datasets https://www.cdc.gov/nchs